| 21.47 Delayed Data As of Jun 26 |  -0.31 / -1.42%Today’s Change | 21.29 Today|||52-Week Range 46.98 | -27.25% Year-to-Date |
| CBM vs. ALKS: Which Stock Should Value Investors Buy Now? Jun 25 / Zacks.comZAK - Paid Partner Content | Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patient... Jun 12 / PR NewswirePRN - Paid Partner Content |
| Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230 Jun 13 / Zacks.comZAK - Paid Partner Content | New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Mult... May 30 / GlobeNewswirePNW - Paid Partner Content |
| Previous close | 21.78 |
| Today’s open | 21.85 |
| Day’s range | 21.40 - 22.18 |
| Volume | 888,393 |
| Average volume (3 months) | 1,144,089 |
| Market cap | $3.5B |
| Earnings growth (last year) | +12.81% |
| Earnings growth (this year) | -44.74% |
| Earnings growth (next 5 years) | +36.45% |
| Revenue growth (last year) | +21.13% |
| P/E ratio | NM |
| Price/Sales | 4.18 |
| Price/Book | 3.00 |
| Today’s change | Today’s % change | |
|---|---|---|
| RAREUltragenyx Pharmaceu... | +0.25 | +0.42% |
| UTHRUnited Therapeutics ... | -0.90 | -1.16% |
| GBTGlobal Blood Therape... | -8.33 | -13.34% |
| TAROTaro Pharmaceutical ... | -1.01 | -1.19% |
| Next reporting date | July 29, 2019 |
| EPS forecast (this quarter) | -$0.13 |
| Annual revenue (last year) | $1.1B |
| Annual profit (last year) | -$139.3M |
| Net profit margin | -12.73% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Richard F. Pops |
Chief Financial Officer & Senior Vice President Jim Frates |
Corporate headquarters Dublin, Dublin |
